Impact of Sustained Virologic Response on Glycemic Control Among Diabetic Patients With Hepatitis C Virus Related Liver Disease

Assiut University140 enrolled

Overview

Hepatitis C virus (HCV) is a major cause of chronic liver disease. The World Health Organization has reported that 170 million people are chronically infected with HCV globally. The highest prevalence of HCV infection worldwide exists in Egypt (15%); 90% of infection among Egyptian patients is due to genotype 4

Study Type

OBSERVATIONAL

Enrollment

140

Conditions

Hepatitis c

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic HCV infection will be diagnosed based on positive testing for serum HCV RNA and anti-HCV Ab. * Diagnosis of type 2 DM will depend on fasting level of serum glucose more than 126 mg/dl and/or serum level of HbA1c more than 6.5 % on oral hypoglycemic therapy. Exclusion Criteria: * Chronic hepatitis due to causes other than HCV infection * Coinfection with HBV infection * Hepatocellular carcinoma * Child C stage of liver cirrhosis. * Patients with type I diabetes mellitus. * Cardiopulmonary diseases. * Major illness. * Patient receiving corticosteroids. * Patient refused consent.

Outcomes

Primary Outcomes

the percentage of patients with glycemic control

Exploring the impact of achieving SVR by directly acting antiviral drugs on glycemic control among diabetic patients with HCV infection.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.